What is HC Wainwright’s Estimate for EBS Q1 Earnings?

Emergent BioSolutions Inc. (NYSE:EBS) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Emergent BioSolutions in a research note issued to investors on Friday, March 21st. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will post earnings per share of $0.87 for the quarter. HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Emergent BioSolutions’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Emergent BioSolutions’ Q2 2026 earnings at $1.04 EPS, Q3 2026 earnings at $1.11 EPS and Q4 2026 earnings at $0.81 EPS.

Separately, StockNews.com cut Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th.

Emergent BioSolutions Stock Performance

NYSE:EBS opened at $5.74 on Monday. Emergent BioSolutions has a twelve month low of $1.82 and a twelve month high of $15.10. The company has a 50-day moving average of $8.41 and a 200-day moving average of $8.72. The firm has a market cap of $311.62 million, a price-to-earnings ratio of -1.40 and a beta of 1.80. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30.

Emergent BioSolutions (NYSE:EBS) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.40. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The company had revenue of $194.70 million for the quarter, compared to analyst estimates of $254.67 million. During the same period in the prior year, the company posted ($0.77) EPS.

Insider Activity

In other news, Director Neal Franklin Fowler sold 35,000 shares of the company’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the sale, the director now directly owns 101,100 shares of the company’s stock, valued at approximately $589,413. This represents a 25.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Emergent BioSolutions

Institutional investors have recently added to or reduced their stakes in the company. State Street Corp boosted its holdings in Emergent BioSolutions by 864.7% in the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock worth $15,960,000 after buying an additional 1,713,200 shares during the period. Oak Hill Advisors LP purchased a new position in shares of Emergent BioSolutions in the third quarter worth $9,296,000. Millennium Management LLC lifted its holdings in Emergent BioSolutions by 83.0% in the 4th quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company’s stock worth $14,167,000 after buying an additional 671,947 shares during the period. Invesco Ltd. increased its position in shares of Emergent BioSolutions by 70.9% during the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company’s stock valued at $14,722,000 after buying an additional 638,995 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Emergent BioSolutions by 67.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company’s stock valued at $10,554,000 after buying an additional 444,790 shares in the last quarter. 78.40% of the stock is owned by institutional investors.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.